A study published in Science Advances demonstrates that weight‑loss and diabetes medicines directly interfere with the mechanisms by which the brain and kidneys maintain fluid homeostasis. GLP‑1 receptor agonists mimic a natural gut hormone, creating a feeling of fullness and prompting insulin release. Beyond glucose metabolism, these drugs reduce levels of vasopressin‑arginine, the key hormone that conserves water, thereby changing the chemical messages sent from the hypothalamus to the kidneys. Patients on these agents often experience increased urinary loss of water and sodium, along with nausea and diarrhea, which can lead to dehydration. Clinicians usually advise generous fluid intake, yet the precise way the drugs interact with fluid‑regulating systems has remained unclear.
Sixteen healthy adults took part in the human arm of the investigation. Blood and urine samples were collected before and after a single dose of liraglutide. Participants also drank a mildly salty solution to provoke modest shifts in hydration. Analysis revealed an acute drop in circulating vasopressin‑arginine after the drug was administered. A concurrent decline in copeptin, a stable fragment released alongside vasopressin, was also observed. Plasma potassium fell, while urinary sodium excretion rose.
Because patients use these medications long‑term, the researchers turned to rodents for chronic observations. Male and female rats received daily injections of liraglutide or saline for 17 days. Food and water intake were recorded each day. In the first hours, liraglutide reduced both food and water consumption, as expected. Over the full 17‑day period, treated rats drank proportionally more water relative to food intake than controls, indicating a disruption of normal hydration patterns.
The team examined hypothalamic and pituitary tissues, the sites of vasopressin synthesis and storage. Gene expression for vasopressin production in the hypothalamus was unchanged, but the pituitary showed a reduced pool of stored hormone. Female rats also displayed lower plasma copeptin after 17 days, suggesting impaired release from the storage site.
To uncover why the pituitary retained less hormone, researchers performed deep proteomic profiling on pituitary extracts taken four hours and 17 days after treatment. Using advanced mass‑spectrometry, they mapped protein abundance and post‑translational phosphorylation, a molecular switch that alters protein function. The profiles differed markedly by treatment duration and sex. At four hours, both sexes showed widespread phosphorylation changes. After 17 days, females exhibited massive remodeling of protein abundance and phosphorylation, whereas males showed fewer alterations. Many affected proteins belonged to pathways governing vesicle formation and hormone secretion. Notably, two proteins that direct the formation of vasopressin‑containing secretory granules acquired distinct phosphorylation marks in females after chronic liraglutide exposure.
To test whether these specific protein modifications directly affect hormone release, the investigators engineered a cell line to express the altered versions of the granule‑guiding proteins observed in the rat pituitary. They introduced a fluorescent reporter that mimics vasopressin release. Cells bearing the modified proteins displayed impaired secretion of the reporter, confirming that the drug‑induced proteomic changes can blunt vasopressin exocytosis.
Overall, the findings reveal a previously unappreciated side effect of GLP‑1 agonists: suppression of vasopressin production and release, leading to altered water and sodium handling. This mechanistic insight helps explain the frequent reports of dehydration‑related symptoms in patients and may guide future strategies to mitigate fluid‑balance disturbances while preserving the metabolic benefits of these drugs.